Summary
A high performance liquid chromatographic method was developed for the quantitative determination of idazoxan in plasma. The assay was used to study the disposition of the drug after intravenous infusion and oral administration to five normal subjects. After i.v. administration the kinetics could be described by a two compartment model with a mean elimination half life of 4.20 h. The mean calculated volume of distribution during the elimination phase was 3.20 l/kg−1 and the mean plasma clearance was 824 ml min−1.
After oral administration a lag period before onset of absorption was observed in all five volunteers, the plasma levels declining monoexponentially from the peak concentration with a mean elimination half life of 5.58 h. The absolute availability varied between 26% and 41% with a mean value of 34%. Invitro measurements produced a blood/plasma ratio of 1.3 for idazoxan.
References
Chapleo CB, Doxey JC, Myers PL, Roach AG (1981) RX781094, a new potent, selective antagonist ofα 2-adrenoreceptors. Proceedings of the British Pharmacological Society 16th–18th September 1981. Br J Pharmacol 74: 842P
Dettmar PW, Lynn AG, Tulloch IF (1981) Neuropharmacological evaluation of RX781094, a new selective α2-adrenoreceptor antagonist. Proceedings of the British Pharmacological Society 16th–18th September 1981. Br J Pharmacol 74: 843P
Gibaldi M, Boyes RN, Feldman S (1971) Influence of first pass effects on availability of drugs on oral administration. J Pharm Sci 60: 1338–1340
Gibaldi M, Perrier D (1975) Drugs and the pharmaceutical sciences, vol 1: Pharmacokinetics. Marcel Dekker, New York, pp 45–55
Hannah JM, Hamilton CA, Reid JL (1983) RX781094, a new potent α2-adrenoreceptor antagonist. In-vivo and in-vitro studies in the rabbit. Naunyn Schmiedeberg's Arch Pharmacol 322: 221–227
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Muir, N.C., Lloyd-Jones, J.G., Nichols, J.D. et al. The pharmacokinetics after intravenous and oral administration in man of theα 2-adrenoreceptor antagonist idazoxan (RX781094). Eur J Clin Pharmacol 29, 743–745 (1986). https://doi.org/10.1007/BF00615972
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00615972